الفهرس 
Introduction, Pathophysiology and Transmission of COVID-19Only 14 pages are availabe for public view
 |  | from | 98 |  |  |
| | | from | 98 | | |
Abstract
ABSTRACT
Background: COVID-19 is a respiratory disease induced by a novel coronavirus (SARS-CoV-2), having already caused more than 2.5 million deaths over the world. Most people with COVID-19 have only mild or uncomplicated symptoms.
Aim and objectives: the aim of the study was to study the effect of using Tocilizumab in treatment of severe cases of COVID-19 in ICU.
Patients and methods: This study is a clinical trial (Analytic, Intervention study, single arm, prospective), this study was carried out at Ain shams university hospitals.
Results: The mean Time to death from receiving Tocilizumab was 6.1888 ± 0.6 SD (Days), the mean Hospital length of stay 14.94 ± 1.85 SD (Days), the number of patients required Mechanical Ventilation was 29 Patients, the mean Duration of mechanical ventilation was 15.19 ± 1.094SD (Days), the number of patients who demonstrated clinical improvement was 38 (73%) and the number of patients who discharged alive was 31 (60%).
Conclusion: In critically ill adult patients with Covid-19 receiving organ support in ICUs, treatment with the interleukin-6 receptor antagonists, Tocilizumab improved outcomes, including survival. Many patients achieved clinical improvement and were eventually discharged from the hospital.